Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

BACKGROUND: In multiple sclerosis (MS), thalamic integrity is affected directly by demyelination and neuronal loss, and indirectly by gray/white matter lesions outside the thalamus, altering thalamic neuronal projections. OBJECTIVE: To assess the efficacy of ocrelizumab compared with interferon beta...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L, Sprenger, Till, Bar-Or, Amit, Wolinsky, Jerry S, Kappos, Ludwig, Kolind, Shannon, Bonati, Ulrike, Magon, Stefano, van Beek, Johan, Koendgen, Harold, Bortolami, Oscar, Bernasconi, Corrado, Gaetano, Laura, Traboulsee, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493406/
https://www.ncbi.nlm.nih.gov/pubmed/35672926
http://dx.doi.org/10.1177/13524585221097561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493406/
https://www.ncbi.nlm.nih.gov/pubmed/35672926
http://dx.doi.org/10.1177/13524585221097561

Ejemplares similares